FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma

Molecular Cancer Therapeutics

Volumn 11, Issue 10, 2012, Pages 2222-2232

  Elkins, Kristi ^a   Zheng, Bing ^a   Go, MaryAnn ^a   Slaga, Dionysos ^a   Du, Changchun ^a   Scales, Suzie J ^a   Yu, Shang Fan ^a   McBride, Jacqueline ^a   De Tute, Ruth ^b,c   Rawstron, Andy ^b,c   Jack, Andrew S ^c   Ebens, Allen ^a   Polson, Andrew G ^a  

^a GENENTECH INC   (United States)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BORTEZOMIB; FC RECEPTOR LIKE 5 PROTEIN; FCRL5 MC VCPAB MMAE ANTIBODY; FCRL5 SPDB DM4 ANTIBODY; LENALIDOMIDE; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; HUMANS; IMMUNOCONJUGATES; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; RECEPTORS, CELL SURFACE; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84867416714     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0087     Document Type: Article

References (24)

1. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J (Sudbury, Mass) 2008;14:154-69.
2. Polakis P. Arming antibodies for cancer therapy. Curr Opin Pharmacol 2005;5:382-7. (Pubitemid 40932040)
3. Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs 2011;20:75-85.
4. Davis RS, Ehrhardt GR, Leu CM, Hirano M, Cooper MD. An extended family of Fc receptor relatives. Eur J Immunol 2005;35:674-80. (Pubitemid 40425522)
5. Dement-Brown J, Newton CS, Ise T, Damdinsuren B, Nagata S, Tolnay M. Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes. J leukoc Biol 2012;91:59-67.
6. Hatzivassiliou G, Miller I, Takizawa J, Palanisamy N, Rao PH, Iida S, et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 2001;14:277-89. (Pubitemid 32289292)
7. Polson AG, Zheng B, Elkins K, Chang W, Du C, Dowd P, et al. Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol 2006;18:1363-73. (Pubitemid 44446830)
8. Inoue J, Otsuki T, Hirasawa A, Imoto I, Matsuo Y, Shimizu S, et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 2004;165:71-81. (Pubitemid 38821815)
9. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
10. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84. (Pubitemid 36791396)
11. Polson AG, Yu SF, Elkins K, Zheng B, Clark S, Ingle GS, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin's lymphoma. Blood 2007;110:616-23. (Pubitemid 47105400)
12. Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004;18:1891-7. (Pubitemid 39530021)
13. Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, Yaccoby S. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J Haematol 2007;138:802-11. (Pubitemid 47313224)
14. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2010;21:5-13.
15. Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, et al. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia 2007;21:169-74. (Pubitemid 44921849)
16. Bartlett NL, Grove LE, Kennedy DA, Sievers EL, Forero-Torres SA. Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: a case series. J Clin Oncol 28: 2010 (suppl; abstr 8062).
17. Burris H, Saleh M, Bendell J, Hart L, Rose A, Dong Z, et al. A phase (Ph) I/II study of CR011-VcMMAE, an antibody-drug conjugate, in patients (Pts) with locally advanced or metastatic breast cancer (MBC) [abstarct]. In: Proceedings of the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2009 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; 2009. Abstract nr 6096.
18. Barclay AN, Brown M, Law SKA, McKinght AJ, Tomlinson MG, Anton van der Merwe P. The leucocyte antigen facts book. San Diego, CA: Academic Press; 1997.
19. Keda H, Hideshima T, Fulciniti M, Lutz RJ, Hiroshi Y, Okawa Y, et al. The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009;15:4028-37.
20. Polson AG, Sliwkowski MX. Toward an effective targeted chemotherapy for multiple myeloma. Clin Cancer Res 2009;15:3906-7.
21. Chanan-Khan AA, Jagannath S, Heffner LT, Avigan D, Lee KP, Lutz RJ, et al. Phase I study of BT062 given as repeated single dose once every 3 weeks in patients with relapsed or relapsed/refractory multiple myeloma. ASH Annual Meeting Poster session Abstracts 2009;114:1862.
22. Younes A, Gordon L, Kim S, Romaguera J, Copeland AR, de Castro Farial S, et al. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed/refractory B-cell non-hodgkin's lymphoma (NHL). ASH Annual Meeting Abstracts 2009;114:585.
23. Chanan-Khan AA, Jagannath S, Munshi NC, Schlossman RL, Anderson KC, Lee K, et al. Phase I study of huN901-DM1 (BB-10901) in patients with relapsed and relapsed/refractory CD56-positive multiple myeloma. ASH Annual Meeting Abstracts 2007;110:1174.
24. Chanan-Khan A, Wolf J, Gharibo M, Jagannath S, Munshi NC, Anderson KC, et al. Phase I study of IMGN901, Used as monotherapy, in patients with heavily pre-treated CD56-positive multiple myeloma - a preliminary safety and efficacy analysis. ASH Annual Meeting Abstracts 2009;114:2883.